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The authors report a retrospective study undertaken in an
effort to characterize the natural history of catheter-associated
upper extremity deep venous thrombosis (CAUEDVT). The find-
ings, although interesting and intriguing, should be interpreted
cautiously. The data indicate that 46% of the patients with
CAUEDVT had documented resolution of thrombus on follow-up
studies. Life-table analysis projected resolution in 73% of patients
at 24 months. The incidence of resolution was significantly de-
creased when the catheter was not removed, whereas anticoagula-
tion did not affect the rate of resolution.
These data, however, may have been influenced by patient
selection. The study was limited to symptomatic patients with
follow-up ultrasound evaluation. Results cannot be extrapolated to
patients with asymptomatic CAUEDVT. The acuity of thrombus
was presumed from clinical presentation alone; characteristics of
the ultrasound examination were not used to distinguish acute and
chronic thrombus. The number of follow-up studies per patient
was small (1.76) and may have been selectively obtained based on
the recurrence of symptoms or the need for additional access.
There was no formal follow-up protocol, and the time-frame for
follow-up studies varied from 1 day to 7.9 years, with one to 10
studies per patient. As a result, the data presented in the life-table
format may not accurately reflect the course of thrombus resolu-
tion.
On the basis of their identified incidence of pulmonary embo-
lism (5%), bleeding complications on anticoagulation (25.8%), and
the observation that anticoagulation did not influence thrombus
resolution, the authors have questioned the utility of anticoagula-
tion in patients with CAUEDVT. Although the recommendations
of this study challenge current conventions,1 the following should
be considered. Anticoagulation was not managed in a standardized
fashion, with identified therapeutic targets; the frequency of ther-
apeutic outliers was not reported. The incidence of bleeding in this
study was high (25.8%) compared with other reported studies.
Outcomes from the REITE initiative (Registro Informatizado de
la Enfermedad TromboEmbolica [Computerized Registry of
Patients With Venous Thromboembolism], a registry of 17,368
consecutive patients with objectively confirmed, symptomaticpatients with DVT.2 Of the 512 patients with upper extremity
DVT, the incidence of major bleeding was only 2.1%; those with
CAUEDVT had a 3.1% incidence of major bleeding.3
The exact incidence of pulmonary embolism associated with
CAUEDVT in this series is uncertain because some patients also
had lower extremity DVT. The reported incidence varies. Monreal
et al4 reported a 16% incidence of pulmonary embolism identified
by V/Q scan 24 hours of the CAUEDVT diagnosis. Munoz et
al3 reported that 9% of patients with armDVT had a clinically overt
pulmonary embolism on presentation; but only a 1.8% recurrence
after 3 months of follow-up. Other series have reported a fre-
quency of 15% to 50% in patients with CAUEDVT.5
The study is challenging and arrives at some intriguing con-
clusions. On the basis of the variability of reported data and
protocols, however, I suspect that these findings should provide
the impetus for further prospective evaluations of the natural
history and management of CAUEDVT rather than drive thera-
peutic change.
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